Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:OMED
Date7/2013
Raised$82M
Post IPO Valuation

General Information

Offices

Redwood City, USA
800 Chesapeake Drive
Redwood City, CA, 94063
USA

People

President and CEO
Vice President, Clinical Research
Vice President, Process Development
Vice President, Translational Medicine
Vice President, Regulatory Affairs
Vice President, General Counsel
Board of Directors
Board of Directors
Show All People

Funding

TOTAL $196M
FUNDING TOTAL $196M
Series B, 11/2008
US Venture Partners
Latterell Venture Partners
The Vertical Group
Morgenthaler Ventures
Adams Street Partners
DeNovo Ventures
Bay Partners
Nomura Phase4 Ventures
$154M
Venture Round, 4/2011
$20M
Venture Round, 12/2013
$22.2M

Competitors

Tags

OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment, by developing monoclonal antibodies that target the biologic pathways critical to tumor initiating cells, also known as “cancer stem cells”. They are leveraging their understanding of these tumor initiating cells to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer.

Recent Milestones

Videos

Screenshots

OncoMed Pharmaceuticals screenshot
Above: OncoMed Pharmaceuticals
Uploaded: 4/20/10

Stock Price

Sources

  1. OncoMed Pharmaceuticals, Inc. Completes $154 Million Series B Financing (biospace.com) [edit]
  2. OncoMed pockets $20M as it takes lead cancer antibody into trial (fiercebiotech.com) [edit]
  3. SEC (sec.gov) [edit]
  4. OncoMed Pharmaceuticals to Sell 4M Shares in IPO (pevc.dowjones.com) [edit]
    Milestone triggers $15 million payment from Bayer to OncoMed (bizjournals.com) [edit]
Edit This Page
Last Edited 3/6/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy